tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ovid Therapeutics Reports Increased Revenue Amid Challenges
PremiumCompany AnnouncementsOvid Therapeutics Reports Increased Revenue Amid Challenges
1M ago
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
Premium
Ratings
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
1M ago
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
Premium
Company Announcements
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
1M ago
Ovid Therapeutics management to meet with B. Riley
PremiumThe FlyOvid Therapeutics management to meet with B. Riley
2M ago
Ovid Therapeutics Approves Key Proposals at Annual Meeting
Premium
Company Announcements
Ovid Therapeutics Approves Key Proposals at Annual Meeting
3M ago
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Premium
Company Announcements
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
3M ago
Ovid Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsOvid Therapeutics Reports Q1 2025 Financial Results
4M ago
Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright
Premium
The Fly
Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright
4M ago
Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100